ライフサイエンスコーパス: anticonvulsant

1 which is currently in use as an FDA-approved anticonvulsant.

2 interneurons essentially insensitive to this anticonvulsant.

3 6) combined with atropine and on occasion an anticonvulsant.

4 (MRS2365) administered at this time point is anticonvulsant.

5 ssion of neuropeptide Y (NPY), an endogenous anticonvulsant.

6 pilocarpine alone, suggesting that SNC80 was anticonvulsant.

7 arbors a potent potassium channel-activating anticonvulsant.

8 py includes tricyclic antidepressants and an anticonvulsant.

9 is a convulsant, but the R-enantiomer is an anticonvulsant.

10 convulsant, whereas R-mTFD-MPPB acted as an anticonvulsant.

11 ccupied by traditional local anesthetics and anticonvulsants.

12 nce seizure generation and responsiveness to anticonvulsants.

13 acting drugs, including antidepressants and anticonvulsants.

14 g no medications; as well as between the two anticonvulsants.

15 tients had seizures, which were treated with anticonvulsants.

16 ncephalopathies that are resistant to modern anticonvulsants.

17 lopmental quotient (DQ) > 30 did not require anticonvulsants.

18 SSRIs and SNRIs; -0.91, -1.23 to -0.60), and anticonvulsants (-0.81, -1.36 to -0.28).

19 %), CCB (14.8% versus 14.4% versus 8.0%) and anticonvulsants (13.4% versus 7.7% versus 6.4%) with OR

20 small compounds: three transplant drugs, an anticonvulsant, a steroid, an anticancer drug, and an an

21 Adenosine is a potent anticonvulsant acting on excitatory synapses through A1

22 We tested leptin's anticonvulsant action in 2 rodent seizure models by dire

23 (E)-2-dodecenal also recapitulated the anticonvulsant action of cilantro, delaying pentylene te

24 n of Cl- transport by bumetanide enables the anticonvulsant action of phenobarbital in immature brain

25 efore tested whether bumetanide enhances the anticonvulsant action of phenobarbital in the neonatal b

26 y gamma-aminobutyric acid receptors and have anticonvulsant action.

27 Acute anticonvulsant actions of 2DG were assessed in vitro in

28 bility to promote anxiolytic, analgesic, and anticonvulsant actions.

29 odents, select compounds exhibited excellent anticonvulsant activities and protective indices (PI=TD5

30 compound class B) exhibited a broad range of anticonvulsant activities in animal models, and in the m

31 drophobic groups and still retain pronounced anticonvulsant activities in rodents in the MES seizure

32 operties of the modified peptides, but their anticonvulsant activities varied substantially and were

33 ileptic drugs (AEDs) that exhibit pronounced anticonvulsant activities.

34 e model of epilepsy and demonstrated in vivo anticonvulsant activity (ED(50) = 8.4 mg/kg) in the mous

35 D, (2R,3R)-SPD, and racemic-SPD have similar anticonvulsant activity and a PK profile that are better

36 f these derivatives were evaluated for their anticonvulsant activity and displayed effective seizure

37 ctivity of these compounds is related to the anticonvulsant activity and implicate neural activity in

38 eospecific comparative pharmacodynamics (PD, anticonvulsant activity and teratogenicity) and pharmaco

39 vation in other neuronal subtypes would have anticonvulsant activity and that intranasal leptin deliv

40 tereoisomers of compound 33 revealed greater anticonvulsant activity by R(+)-33 enantiomer in both ME

41 in vivo effects in assays for locomotion and anticonvulsant activity correlated fairly well with its

42 F1,6BP had dose-dependent anticonvulsant activity in all three models, whereas VPA

43 ained agonist activity, and exhibited potent anticonvulsant activity in mice following intraperitonea

44 ained compounds 30-32, which produced potent anticonvulsant activity in mouse seizure models, includi

45 oxy-5alpha-pregnan-20-one), exhibit enhanced anticonvulsant activity in perimenstrual catamenial epil

46 antiepileptic drug, has shown broad-spectrum anticonvulsant activity in preclinical studies and seizu

47 Compound 4 exhibited excellent anticonvulsant activity in rodents against audiogenic, e

48 This compound exhibited excellent anticonvulsant activity in rodents against audiogenic, e

49 Compound 33 showed the highest anticonvulsant activity in these models (ED50 MES = 79.5

50 The anticonvulsant activity loss that accompanied introducti

51 ock in the glycolytic pathway, abolished the anticonvulsant activity of 2-DG in the pilocarpine model

52 The anticonvulsant activity of F1,6BP was determined in rat

53 Because the anticonvulsant activity of galanin is mediated by the re

54 dition, block of Na(V)1.2 may complement the anticonvulsant activity of Na(V)1.6 inhibition.

55 Prior work demonstrated anticonvulsant activity of SGE-516 in acute seizure assa

56 seizure protection in mice, and like (R)-2, anticonvulsant activity principally resided in the (R)-s

57 SPD stereoisomers' anticonvulsant activity was comparatively evaluated in s

58 of 19 carbamates was synthesized, and their anticonvulsant activity was comparatively evaluated in t

59 Significant anticonvulsant activity with little or no motor impairme

60 e relationship between the LAA structure and anticonvulsant activity, orthogonally protected LAAs wer

61 -9, 10a-i, 11a, 11b, 12) and evaluated their anticonvulsant activity.

62 und N(6) suitable for an A(1)AR agonist with anticonvulsant activity.

63 t-selective GABA(A)R modulator with low-dose anticonvulsant activity.

64 e thresholds dose-dependently, indicative of anticonvulsant activity.

65 osphate pathway, it was hypothesized to have anticonvulsant activity.

66 es, i.e., 3 (a-e) and 5 (a-e) and evaluated, anticonvulsant activity.

67 pigenetic function of the brain's endogenous anticonvulsant adenosine, showing that this compound ind

68 Adults not taking enzyme-inducing anticonvulsants after resection or biopsy of GBM were tr

69 includes administration of a benzodiazepine anticonvulsant agent (e.g. diazepam) and/or physical coo

70 YNA), a well established neuroprotective and anticonvulsant agent, involved in synaptic transmission

71 din-1-yl)butanamides as potential new hybrid anticonvulsant agents was synthesized.

72 psychotropic classes (e.g., antidepressants, anticonvulsants), although they may be safer options.

73 ues in patients treated with enzyme-inducing anticonvulsants, although this did not reach statistical

74 Total synthesis of anticonvulsant amino acid, lacosamide, is reported.

75 methyl)-5-methylhexanoic acid, Lyrica] is an anticonvulsant and analgesic medication that is both str

76 idely prescribed short chain fatty acid with anticonvulsant and anticancer properties, remains poorly

77 Our results show that 2DG has anticonvulsant and antiepileptic properties, suggesting

78 The glycolytic inhibitor 2DG exerts acute anticonvulsant and chronic antiepileptic actions, and ha

79 arget therapies are unlikely to provide both anticonvulsant and disease-modifying effects.

80 d by valproic acid (VPA), a mood-stabilizer, anticonvulsant and histone deacetylase (HDAC) inhibitor,

81 ncreasing levels of adenosine, an endogenous anticonvulsant and neuroprotective molecule, might help

82 therapy may be helpful, in terms of both an anticonvulsant and possibly a neuroprotective effect.

83 uggests that targeting the P2X7 receptor has anticonvulsant and possibly disease-modifying effects in

84 naling and are thus targeted by a variety of anticonvulsant and relaxant drugs.

85 everity is reversed, with the antagonist now anticonvulsant and the agonist proconvulsant.

86 y distinguish between patients taking either anticonvulsant and those taking no medications; as well

87 Anticonvulsant and tricyclic antidepressant drugs are fi

88 Treatment with anticonvulsants and age were associated with greater odd

89 Evidence supports the use of specific anticonvulsants and antidepressants for pain management

90 ly important compounds, including diuretics, anticonvulsants and antidepressants, many of which have

91 rmined that the recommendations from the CNS anticonvulsants and steroids guidelines, published Janua

92 drugs with a focus on the controlled use of anticonvulsants and steroids.

93 allosterically modulated by the anxiolytic, anticonvulsant, and sedative-hypnotic benzodiazepines.

94 ceptor are important anesthetics, sedatives, anticonvulsants, and anxiolytics.

95 es occur frequently, are often refractory to anticonvulsants, and are associated with considerable mo

96 Clinicians should utilize omega-3, anticonvulsants, and atypical antipsychotic agents in tr

97 inistration of uterotonics, antibiotics, and anticonvulsants, and clean birth environments) would acc

98 asses of clinical agents (e.g., anxiolytics, anticonvulsants, and general anesthetics) that act as po

99 inhibitors, cinchona alkaloids, antibiotics, anticonvulsants, and heparin.

100 etrovirals, antidepressants, antipsychotics, anticonvulsants, and immunosuppressants for transplant p

101 neurological symptoms, with gabapentin-type anticonvulsants, and is among the first in nonepileptic

102 hotics for schizophrenia and antipsychotics, anticonvulsants, and lithium for bipolar disorder.

103 Antiarrhythmics, anticonvulsants, and local anesthetics target voltage-ga

104 reatments include tricyclic antidepressants, anticonvulsants, and opioids, depending on the severity

105 rugs and contraceptives are rare, clozapine, anticonvulsants, and St.

106 ivity was comparatively evaluated in several anticonvulsant animal models including the benzodiazepin

107 ntral and the peripheral nervous systems has anticonvulsant, anti-inflammatory, and analgesic propert

108 utic drugs and supportive-care drugs-such as anticonvulsants, antiemetics, uric-acid-lowering compoun

109 17-3.81; P for trend < .001), whereas use of anticonvulsants, antipsychotics, or antidepressants was

110 olam, an anesthetic BDZ, with clonazepam, an anticonvulsant/anxiolytic BDZ that activates CBRs select

111 the KCNQ2-5 channel activator retigabine, an anticonvulsant approved by the U.S. Food and Drug Admini

112 These anticonvulsants are neutral, in contrast to the mostly p

113 Broad-spectrum anticonvulsants are of considerable interest as antiepil

114 on as antinociceptive, antiinflammatory, and anticonvulsant as well as antiinfective agents.

115 Maintenance treatment with lithium or anticonvulsants as practiced in modern care is associate

116 PURPOSE OF REVIEW: Despite myriad anticonvulsants available and in various stages of devel

117 ney disease, or diabetes and subjects taking anticonvulsants, barbiturates, or steroids.

118 de: antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotic

119 (+)-alpha (-) sites, whereas loreclezole, an anticonvulsant, binds with 5- and 100-fold higher affini

120 dditional commonly used Na(+) channel-acting anticonvulsants, both in control and epileptic animals.

121 The anticonvulsant carbamazepine 1 is associated with advers

122 ies and other risk factors, among individual anticonvulsants compared with topiramate and secondarily

123 igation of neuroactive steroids as potential anticonvulsant compounds for refractory epilepsies.

124 dal-rostral developmental pattern, GABAergic anticonvulsant compounds inhibit motor manifestations of

125 different mode and site of action than other anticonvulsant compounds.

126 alanin analogues yielded systemically active anticonvulsant compounds.

127 We report that carbamazepine, an anticonvulsant, corrects the trafficking defects of muta

128 .80-3.42; P for trend < .001), as was use of anticonvulsants (definite CKD, 1-2 prescriptions: HR = 1

129 unds represent novel leads in the search for anticonvulsants devoid of sedative, ataxic, and amnestic

130 icus, which was decreased in severity by the anticonvulsant diazepam.

131 a is provided by modern antipsychotics, some anticonvulsants (divalproex and carbamazepine), and lith

132 Ethosuximide (ETH), an anticonvulsant drug is used for the treatment of epilept

133 that are associated with the binding of the anticonvulsant drug Lamotrigine and batrachotoxin are al

134 The effect of gabapentin, an anticonvulsant drug that is also effective in pain and a

135 Valproic acid (VPA) is an anticonvulsant drug that is also used to treat migraines

136 on to die of their disease respond poorly to anticonvulsant drug therapy, suggesting a need for new t

137 condition can be induced without concomitant anticonvulsant drug treatment.

138 We have previously shown that the anticonvulsant drug valproate (VPA) depletes inositol by

139 This study focuses on carbamazepine, an anticonvulsant drug which is ubiquitously detected in re

140 the most cold sensitive was lamotrigine, an anticonvulsant drug.

141 We have, therefore, studied the effects of anticonvulsant drugs acting via use-dependent block of v

142 Many currently used anticonvulsant drugs are known to exert potent use-depen

143 In many epileptic patients, anticonvulsant drugs either fail adequately to control s

144 With an increasing number of anticonvulsant drugs it is likely that patients may not

145 efractory convulsive status epilepticus, the anticonvulsant drugs levetiracetam, fosphenytoin, and va

146 The tricyclic anticonvulsant drugs phenytoin, carbamazepine, and lamot

147 izures and can be refractory to conventional anticonvulsant drugs, suggesting an age-specific form of

148 sed as local anesthetic, antiarrhythmic, and anticonvulsant drugs.

149 in producing the mood-stabilizing effects of anticonvulsant drugs.

150 ful reduction of CNS excitability exerted by anticonvulsant drugs.

151 l rendered WSP mice less sensitive to ALLO's anticonvulsant effect and more sensitive to FIN's procon

152 terations in metabolism, as evident from the anticonvulsant effect of diets that reduce glucose utili

153 EtOH exposure, WSP mice were tolerant to the anticonvulsant effect of intra-hippocampal ALLO infusion

154 icacious than bumetanide in potentiating the anticonvulsant effect of phenobarbital.

155 The full anticonvulsant effect of the ketogenic diet (KD) can req

156 enous peptide ligand galanin exerts powerful anticonvulsant effect through activation of these two G

157 the pentose phosphate pathway, would have an anticonvulsant effect.

158 ologies in adolescent rats to understand its anticonvulsant effect.

159 of VPA-treated mice with retigabine induced anticonvulsant effects even when administered after seiz

160 ppress this pathway may be important for its anticonvulsant effects in AGS-kindled GEPR-9s, and this

161 -releasing hormone (TRH) is reported to have anticonvulsant effects in animal seizure models and cert

162 AP has enhanced anticonvulsant effects in fully kindled wild-type mice,

163 ough ALAC or NaB administration has specific anticonvulsant effects in PTZ-treated mice.

164 vestigated the potential neuroprotective and anticonvulsant effects of compounds acting on mGlu II re

165 citability are proposed to contribute to the anticonvulsant effects of LEV.

166 also showed a trend toward tolerance to the anticonvulsant effects of lorazepam.

167 Here, we report that the anticonvulsant effects of nonacute VPA treatment involve

168 e-induced seizure transiently eliminated the anticonvulsant effects of VPA.

169 pen receptor-suppressed M-channels, provided anticonvulsant effects only when administered prior to s

170 Anticonvulsant effects were observed in vivo with compou

171 ggest that cannabidiol could be exerting its anticonvulsant effects, at least in part, through its ac

172 Propofol and desflurane have reliable anticonvulsant effects, whereas remifentanil in larger d

173 The anticonvulsant efficacy of phenobarbital, bumetanide, an

174 These data underscore the broad-spectrum anticonvulsant efficacy of this circuit, and demonstrate

175 data demonstrate that F1,6BP has significant anticonvulsant efficacy.

176 clohex-3-en-6-methyl-2-oxo-1-oate (E139), an anticonvulsant enaminone, has antinociceptive activity i

177 convulsant M-channel blocker linopirdine and anticonvulsant enhancer retigabine display increased and

178 aging or EEG), prophylactic antipyretics and anticonvulsants far outweigh their potential benefits.

179 Valproic acid (VPA) is a widely prescribed anticonvulsant for the treatment of epilepsy.

180 n is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive st

181 The anticonvulsant gabapentin is effective in reducing the s

182 Lacosamide, a recently approved anticonvulsant, has unique effects on sodium channels th

183 the brain and act as endogenous anxiolytic, anticonvulsant, hypnotic, and sedative agents, actions t

184 Lacosamide is an anticonvulsant hypothesized to enhance slow inactivation

185 emperature, allowed for the synthesis of the anticonvulsant ilepcimide with up to 96 % conversion.

186 o phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive

187 ge underlying precipitant causes, administer anticonvulsants in rapid succession until seizures have

188 ation, and for prophylactic antipyretics and anticonvulsants, in the majority of children with simple

189 ampal infusion of ALLO (0.1 microg/side) was anticonvulsant, increasing the threshold dose of PTZ for

190 the most teratogenic of commonly prescribed anticonvulsants, increasing the risk in humans of major

191 ds, acetaminophen, anti-inflammatory agents, anticonvulsants, ketamine, clonidine, mexiletine, antide

192 The anticonvulsant lacosamide acts on Nav1.3, Nav1.7, and Na

193 t chemistries, were suspect-screened for the anticonvulsant lamotrigine (LMG), its metabolites, and r

194 The structurally different anticonvulsant lamotrigine and one of its derivatives ha

195 zapine + fluoxetine, and quetiapine) and the anticonvulsant lamotrigine; value and safety of antidepr

196 o change treatment to one of the noninducing anticonvulsants lamotrigine or levetiracetam.

197 class of selective KCNQ2/Q3 activators with anticonvulsant-like activity in experimental models of e

198 re antidepressants, atypical antipsychotics, anticonvulsants, lithium, and other medications used in

199 ior, in addition to concerns that the use of anticonvulsants may increase self-harm.

200 We propose an anticonvulsant mechanism of the KD involving mitochondri

201 romodulator adenosine is a potent endogenous anticonvulsant mechanism, which limits the extension of

202 Anticonvulsant mechanisms of the ketogenic diet remain i

203 Carbamazepine (CBZ) is an anticonvulsant medication with highly persistent propert

204 There was no correlation with withdrawal of anticonvulsant medication, and death certificate informa

205 ved in two-thirds of cases by treatment with anticonvulsant medication, surgical resection, and/or ne

206 e start of drug infusion, without additional anticonvulsant medication.

207 atus epilepticus in children, including both anticonvulsant medications and overall management approa

208 eviews suggest a role for antidepressant and anticonvulsant medications for neuropathic pain, but the

209 Administration mandated warning labeling for anticonvulsant medications regarding the increased risk

210 was to determine whether zonisamide, another anticonvulsant mood stabilizer, as well as lithium, a mo

211 dicate the potential clinical utility of the anticonvulsant mood stabilizer, valproate, in bipolar di

212 We have recently reported that the anticonvulsant mood stabilizers (AMS), valproic acid, ca

213 Anticonvulsant mood stabilizers, e.g., valproic acid and

214 Antipsychotic drugs (APD)s and anticonvulsant mood-stabilizers are now frequently used

215 g. clozapine and risperidone, as well as the anticonvulsant mood-stabilizers, valproic acid (VPA), zo

216 tabilizing agents but only those, which have anticonvulsant mood-stabilizing properties, increase DA

217 ffairs Risk Score-CVD, and antipsychotic and anticonvulsant/mood stabilizer medication prescriptions.

218 ts exposed to either lithium (n = 26,731) or anticonvulsants (n=420,959).

219 y was attributable to greater release of the anticonvulsant neuropeptide, neuropeptide Y (NPY).

220 Some drugs developed as anticonvulsants (notably, valproate and lamotrigine) hav

221 ds for chronic noncancer pain, compared with anticonvulsants or cyclic antidepressants, was associate

222 for long-acting opioids or either analgesic anticonvulsants or low-dose cyclic antidepressants (cont

223 psychotics, combinations of antidepressants, anticonvulsants, or "other") for >/=60 consecutive days

224 in 297,620 new episodes of treatment with an anticonvulsant (overall median follow-up, 60 days).

225 ose of irinotecan was based on the patient's anticonvulsant: Patients taking enzyme-inducing antiepil

226 The widely used anticonvulsant pharmaceutical carbamazepine is recalcitr

227 We report that a barbiturate anticonvulsant, phenobarbital, alleviates the effect of

228 , which was similar to that observed for the anticonvulsants phenytoin (slowly binds to the fast-inac

229 The widely prescribed anticonvulsants phenytoin and carbamazepine are potent i

230 The activity reduction by an anticonvulsant, phenytoin, was also localised to treated

231 s is a mechanistic demonstration of rational anticonvulsant polypharmacy.

232 ibitors--duloxetine and milnacipran--and the anticonvulsant pregabalin are encouraging.

233 here was a small but significant increase in anticonvulsant prescriptions (rate, 0.117; 95% CI, 0.08-

234 The anticonvulsant profile of 4 suggests that it may be usef

235 Proconvulsant and anticonvulsant properties have been reported for virtual

236 evidence that glycine can have both pro- and anticonvulsant properties in various rodent models of ep

237 We describe here the anticonvulsant properties of 8,9-dihydrocannibidiol (H2C

238 s well as lithium, a mood stabilizer without anticonvulsant properties, also increases prefrontal cor

239 In addition, some compounds exhibit anticonvulsant properties.

240 ntin is a structural analog of GABA that has anticonvulsant properties.

241 n principal hippocampal neurons and displays anticonvulsant properties.

242 A key role for kappa opioids in anticonvulsant protection provides a framework for explo

243 In contrast, only the anticonvulsant R-enantiomer binds to the enhancing site

244 opionamide, (R)-1) is a low molecular weight anticonvulsant recently introduced in the United States

245 Conventional anticonvulsants reduce neuronal excitability through eff

246 Phenobarbital had insignificant anticonvulsant responses in the neocortex until NKCC1 wa

247 and limited human data suggest an important anticonvulsant role for opioid peptides and their recept

248 Consistent with an anticonvulsant role, the ketone body effect is larger fo

249 stitute of Neurological Disorders and Stroke Anticonvulsant Screening Program for seizure protection

250 This model also exhibited anticonvulsant sensitivity similar to in vivo models.

251 ng at very high rates, suggesting that these anticonvulsants should cause impaired GABAergic inhibiti

252 TCAs (SMD, -0.78 [CrI, -1.24 to -0.33]), and anticonvulsants (SMD, -0.67 [CrI, -0.97 to -0.37]) were

253 epinephrine reuptake inhibitors (SNRIs) than anticonvulsants (standardized mean difference [SMD], -0.

254 ation of action in the performed time course anticonvulsant studies, being nontoxic in subacute toxic

255 ng-term relapse prevention; the evidence for anticonvulsants such as divalproex and lamotrigine is le

256 lectroencephalographic response to GABAergic anticonvulsants such as phenobarbital and benzodiazepine

257 eclude the efficacy of widely used GABAergic anticonvulsants such as phenobarbital.

258 ndrial GABA content and its modulation by an anticonvulsant, swimming-evoked, GABA-mediated transmiss

259 that SF0034 was a more potent and less toxic anticonvulsant than retigabine in rodents.

260 Retigabine is a recently approved anticonvulsant that acts by potentiating neuronal M-curr

261 Valproic acid is a widely used anticonvulsant that has recently been approved for stabi

262 CBZ) and oxcarbazepine (OXC) are widely used anticonvulsants that are extensively metabolized in the

263 activity in the cortex is not suppressed by anticonvulsants that block the transmission of seizure a

264 tribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and ma

265 two of which are approved for human use, are anticonvulsants that modulate neural activity.

266 Except for anticonvulsants, the adjusted risks for all individual c

267 s could point to molecular targets for novel anticonvulsant therapies.

268 potential use of K(v)7 openers as a targeted anticonvulsant therapy to improve developmental outcome

269 ides a starting point for the development of anticonvulsant therapy using the galanin R2 receptor as

270 ls; antidepressant tranylcypromine (2.15 A), anticonvulsant thioperamide (1.65 A), antifungal voricon

271 is to stop the seizures quickly enough with anticonvulsants to prevent brain damage.

272 In seeking broad-spectrum anticonvulsants to treat epilepsy and other neurological

273 Propranolol, the beta-blocker, and the anticonvulsant topiramate are effective for migraine pre

274 to treatment with tricyclic antidepressants, anticonvulsants (topiramate), coenzyme Q-10, and L-carni

275 seizures that are resistant to conventional anticonvulsant treatment but are well-controlled by pyri

276 tors of remote seizures and active epilepsy (anticonvulsant treatment for remote seizure within prior

277 into why spontaneous seizures remit without anticonvulsant treatment.

278 JAK2/PI3K signaling may be novel targets for anticonvulsant treatments.

279 has also been mandated to be applied to all anticonvulsant trials and other centrally acting agents

280 sy had a recent breakthrough seizure despite anticonvulsant usage.

281 ), depression (HR, 1.30; 95% CI, 1.05-1.61), anticonvulsant use (HR, 1.35; 95% CI, 1.04-1.75), and la

282 energy injury (OR, 1.38; 95% CI, 1.27-1.49), anticonvulsant use (OR, 1.37; 95% CI, 1.31-1.43), osteop

283 Steroid treatment and anticonvulsant use were related to poorer CCRI performan

284 oid arthritis (OR, 1.58; 95% CI, 1.38-1.82), anticonvulsant use with benzodiazepines (OR, 1.49; 95% C

285 epression, abnormal renal or liver function, anticonvulsant use, labile international normalized rati

286 , attempted suicides, and violent deaths for anticonvulsants used in at least 100 treatment episodes

287 prenatal exposure to the highly teratogenic anticonvulsant valproic acid (VPA) significantly increas

288 illness, use of antidepressants, and use of anticonvulsants versus lithium.

289 reased rate of end-stage CKD, whereas use of anticonvulsants was (1-2 prescriptions, HR = 0 [95% CI,

290 ,5-diones as potential broad-spectrum hybrid anticonvulsants was described.

291 nonketotic hyperglycinemia required multiple anticonvulsants, whereas patients with developmental quo

292 ribute an important component to binding for anticonvulsants, which compensates energetically for the

293 ical conditions, such as antidepressants and anticonvulsants, which were found empirically to be effe

294 tassium channels, we have docked these three anticonvulsants with residues identified by mutagenesis

295 onepileptic patients, suggesting that sudden anticonvulsant withdrawal alone, unaccompanied by seizur

296 velop in some epileptic patients after rapid anticonvulsant withdrawal.

297 This case is the first to associate anticonvulsant-withdrawal splenial abnormalities with ne

298 eatment step and a higher cumulative dose of anticonvulsants within the first period of treatment wer

299 mnolence and dizziness with TCAs, SNRIs, and anticonvulsants; xerostomia with TCAs; and peripheral ed

300 have a long history of use as folk medicine anticonvulsants, yet the underlying mechanisms often rem